S

Sanofi

Global pharma company; vaccines and R&D

Area Business Manager - Pulmonary

Full-TimeUpdated on 10/23/2026Deadline 11/30/26
$125.3k - $180.9k
Mid
Bachelor's
London, KY, USA
In PersonTravel to meetings, training, programs, and within the assigned territory may be required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree from an accredited four-year college or university.
  • At least 3 years of pharmaceutical, biotech, or medical device sales experience.
  • Demonstrated ability to learn and apply technical and scientific product-related information.
  • Ability to travel to meetings, training, and programs as necessary, with additional travel potentially required within the assigned territory.
  • Proven success and a positive track record of consistent sales performance in complex markets with diverse customer segments, operating with a high degree of integrity within compliance guidelines.
  • Ability to cooperate with collaboration partners and internal colleagues to reach common goals.
  • A valid driver's license.
Responsibilities
  • Engage pulmonary customers within the assigned geographical territory and deliver clinically focused messages to introduce, launch, and grow brand share and revenue, and consistently deliver product goals for the asthma indication.
  • Collaborate and coordinate with field-based stakeholders, including Regeneron Sales Professional counterparts, Medical Science Liaisons, Field Reimbursement and Market Access teammates, and Thought Leader Liaisons, to address customer needs, identify market dynamics and trends, develop strategies supporting brand and corporate objectives, and ensure account success within the assigned geography.
  • Develop working relationships with pulmonary experts, biologic coordinators, office staff, other healthcare personnel, and key patient advocacy support groups as directed.
  • Identify key opportunities and develop strategic business plans to generate product utilization and grow territory business.
  • Plan, organize, and execute local promotional speaker programs and activities.
  • Maximize the budget allocated to the geographic territory to support strategy execution and generate or grow business.
  • Participate in and help lead assigned initiatives supporting sales success, including industry-related congresses, local and regional meetings, and medical conferences.
  • Own business opportunities within the geographic area, including coordinating and calling upon large group practices and other key targets to drive product results.
  • Establish relationships with thought leaders in the assigned territory.
  • Drive industry-leading customer value.
Desired Qualifications
  • Two years of selling subcutaneous self-injectable or office-administered intravenous biologics.
  • Two years of selling experience in pulmonary disease or other immunology disorders, such as atopic dermatitis, psoriasis, multiple sclerosis, Crohn's disease, or ulcerative colitis.
  • Two years of selling experience calling on pulmonologists.
  • Co-promotion experience.
  • Advanced clinically based selling skills.
  • A results-oriented approach with a proven track record of success with product launches.
  • Experience in-service training office staff, nurses, and office managers.
  • A passion and aptitude for learning science, and proactivity in strengthening knowledge related to disease state, treatment options, and healthcare trends.
  • Strong organization and account management skills.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...